Page 72 - Genentech News Today

/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has signed a...

The total metastatic HER2-positive breast cancer market size in the 7MM was estimated to be nearly USD 2.6 billion in 2022, which is expected to show positive...

With AI taking off, Nvidia's pioneering efforts in the accelerated computing space are paying off. Today, Nvidia's platform is used by 4.5 million developers and powers 76% of the TOP500 supercomputers. The company recently announced very strong quarterly results. Nvidia's Financials Nvidia's third quarter revenues grew a jaw dropping 206% to $18.12 billion, ahead of market estimates of $16.18 billion. Non GAAP EPS was $4.02, also ahead of market estimates of $3.37. By segmen...

Biopharma executive with proven track record brings substantial strategy, business development, and licensing experience to AbTherx leadership teamMOUNTAIN VIEW, CA / ACCESSWIRE / November 28, 2023 / AbTherx, a privately held biotech company with ...

PagerDuty recognized as Marketplace Partner of the Year - North America “NAMER” winner ...

In its fifth year, the 40 Under 40 program celebrates the industry’s most highly regarded young talent.

The artificial intelligence leader's management talks China AI product export regulations and recurring revenue streams.

Elecsys® HBeAg quant is an immunoassay that can be used as an early marker of acute hepatitis B infection, as well as an indicator of chronic active...

The global PD L1 biomarker testing market is expected to touch US$ 14.2 billion by 2030, with an annual growth rate of more than 16.5% says RationalStatWilmington, Delaware, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Global PD L1 Biomarker Testing Market is valued at US$ 4.9 billion in 2023 and is expected to grow at a significant CAGR of over 16.5% over the forecast period of 2023-2030, according to the published market report by RationalStat Market Definition, Market Scope, and Report Overview Programm

Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers. Data from several recent phase 3 trials support changes to standard care for NSCLC, according to researchers.